Because of this dual-pathway approach, many patients experience faster weight loss, stronger appetite control, and improved metabolic response
The technical term is it's a GLP-1 receptor agonist, and just like GLP-1, it increases insulin release, it lowers blood sugar, the stomach empties slower, but it was different from GLP-1 in one really important way
This means moving away from dieting and toward nutrient-dense eating
Taylor SI (2020) The high cost of diabetes drugs: disparate impact on the most vulnerable patients
All you need is help
Patients seeking GLP-1 therapy should rely on FDA-approved medications with established efficacy profiles, including landmark trials like STEP (semaglutide) demonstrating approximately 15% body weight reduction and SCALE (liraglutide) showing 5-8% weight reduction, along with improved glycemic control in patients with diabetes